.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01F_MonoclonalAntibodiesAndAntibodyDrugConjugates.L01FF11_Sugemalimab.Sugemalimab .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01F_MonoclonalAntibodiesAndAntibodyDrugConjugates.L01FF11_Sugemalimab.Sugemalimab| name: | Sugemalimab |
| ATC code: | L01FF11 | route: | intravenous |
| n-compartments | 2 |
Sugemalimab is a humanized monoclonal antibody targeting PD-L1, used as an immune checkpoint inhibitor in cancer therapy, particularly for non-small cell lung cancer (NSCLC). It is approved for medical use in China and is undergoing further clinical investigation globally.
Population pharmacokinetic parameters in adult patients with advanced solid tumors and lymphoma, as assessed in clinical trial population.